Patient-centered outcomes in the acute treatment of migraine: a prospective, real-world, longitudinal survey study (UNIVERSE II) comparing migraine patients who switch from a prior triptan to another triptan or ubrogepant.

ABSTRACT:

Objective

Evaluate the real-world experience of ubrogepant versus triptans for the acute treatment of migraine among participants switching from an oral triptan.

Methods

UNIVERSE II was a prospective, longitudinal, survey-based, real-world study conducted in adult Migraine Buddy application users who self-reported a switch from an oral triptan to another oral triptan or ubrogepant. The 4-week study assessed treatment satisfaction, preference for the new treatment or previous triptan, and patient experience with new treatment against previous triptan.

Results

Of 694 participants, 211 were included after screening and accounting for dropouts (triptan, n = 100; ubrogepant, n = 111). At Day 30, significantly greater proportion of the ubrogepant cohort report

SUBMITTER: Lipton RB 

PROVIDER: S-EPMC12773619 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature